This is the authors' abstract. We don't add key points for this paper.
The virus validation of three steps of Biotest Pharmaceuticals IGIV production process is described here. The steps validated are precipitation and removal of fraction III of the cold ethanol fractionation process, solvent/detergent treatment and 35 nm virus filtration. Virus validation was performed considering combined worst case conditions. By these validated steps sufficient virus inactivation/removal is achieved, resulting in a virus safe product.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dichtelmüller et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: